Some references about the Zohydro controversy [a big mistake…]…
- New FDA Chief Must Divest Several Stock, Fund Holdings
- Margaret Hamburg, Wikipedia
- FDA chief urges ‘new era of partnership’
- FDA commissioner defends proposal to expedite drug approval for serious illnesses
- FDA Chief Defends Approval of Controversial Painkiller
- Sen. Elizabeth Warren Takes FDA Chief To Task On Weak Antibiotics Guidance
- New Painkiller Rekindles Addiction Concerns
- Critics Oppose FDA Approval of Painkiller Zohydro
- Gov. Deval Patrick Issues Tighter Restrictions for Painkiller Zohydro
- Understanding the uproar over Zohydro ER
- Critics Question FDA’s Approval Of Zohydro
- Zohydro Update
- Zogenix Makes Moves to Concentrate on Its Zohydro Efforts, Sells Migraine Therapy Business
hat tip to jamzo… 
The comment on the Boston Globe article (third link down) is of interest:
http://www.bostonglobe.com/business/2014/04/04/fda-commissioner-calls-for-new-era-partnership-with-biopharma-industry/8676GZuMw8oEqaXt2HmkmK/comments.html
This is what happens when pharma is allowed to push its message of a pill for every person and every person taking a pill. Decades ago I was warned that salesmen want to sell and they do not care what they sell. This is how they get their job rush.
This drug will be no different.
http://health.foxnews.mobi/quickPage.html?page=31737&content=103494415&pageNum=-1
Steve Lucas
It’s not a pill for every person, it’s a pill for every symptom.
I stand corrected.
Steve Lucas
I don’t like this at all. The SEC is in a partnership with investment banks. We know how that works out.
On the other hand, it shouldn’t take 1.5 billion dollars and 15 years to get a drug approved.
New treatments that are not me too drugs should be approved after a safety trial and let the clinicians argue about efficacy.